Clin2
NCT06816914Possibly a fitRecruiting

Perioperative chemo for resectable pancreatic cancer

Resectable Pancreatic Adenocarcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
84 people
Ages
20 years to 75 years
Study type
Interventional

Who can take part

  • You have been diagnosed with pancreatic cancer that has not spread beyond the pancreas and is surgically removable.
  • You are between 20 and 75 years old.
  • You have not received any prior treatment for your pancreatic cancer.
  • Your overall health is good (able to perform daily activities without help).
  • You have not had a heart attack, stroke, or serious heart problems in the last 6 months.
  • You agree to use effective birth control if applicable, and you are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07034703Not yet recruiting
Chemo before surgery for potentially resectable pancreatic cancer

This trial tests 6 cycles of a chemotherapy combination called modified FOLFIRINOX before surgery for pancreatic cancer that can potentially be removed. The goal is to see if this approach improves outcomes for patients who might be candidates for another study called PANACHE02.

Rouen, France
NCT06210360Not yet recruiting· Phase 2
Chemotherapy before and after surgery for high-risk pancreatic cancer

This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.

NCT06172036Not yet recruiting· Phase 2
Irinotecan and immunotherapy for resectable pancreatic cancer

This trial tests adding a new immunotherapy drug (addebelizumab) to standard chemotherapy for people with pancreatic cancer that can be removed by surgery. The goal is to see if the combination shrinks tumors more effectively before surgery.

NCT07044453Recruiting· Phase 2/Phase 3
Extra chemo tailored to tumor stage for operated pancreatic cancer

This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.

Rouen
NCT03322995Recruiting· Phase 2
Neoadjuvant chemo study for resectable pancreatic cancer

This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.

Milwaukee, Wisconsin
NCT06387810Recruiting· Phase 2
Chemo before and after surgery for borderline resectable pancreatic cancer

This trial tests a combination of chemotherapy drugs (irinotecan liposome, 5-FU, leucovorin, and oxaliplatin) given before and after surgery for people with pancreatic cancer that is on the border of being removable. The goal is to see if this treatment helps shrink the tumor and improve outcomes.

Beijing, Beijing Municipality

Hear when a new Resectable Pancreatic Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.